HomeNewsBusinessInterview | British firms feel 'Aatmanirbhar Bharat' provides more investment opportunities: UKIBC Chief

Interview | British firms feel 'Aatmanirbhar Bharat' provides more investment opportunities: UKIBC Chief

While they may not completely move supply chains from China, 77% of British companies surveyed by UKIBC feel they can invest more in India to augment their Chinese facilities

March 12, 2021 / 14:12 IST
Story continues below Advertisement

As the pandemic recedes, British investors are exploring India as an additional manufacturing location with a China +1 model, rather than fully dislocating from China, said Jayant Krishna, Chief Executive Officer of the United Kingdom India Business Council (UKIBC), in an exclusive interview with Moneycontrol.

After initial hesitations over the government's Aatmanirbhar Bharat policy being a protectionist move, UK firms now feel it would lead to greater integration of India’s economy with the rest of the world. More investments by British firms in sectors ranging from pharmaceuticals, defence and engineering to higher education may be the result, Krishna pointed out.

Story continues below Advertisement

In fact, 2020 saw a sharp uptick in interest from British investors exploring the Indian market, he added.

As trade talks between both nations intensify, the CEO stressed that incremental reforms, meaning the removal of market access issues, removal of barriers to trade and improving the ease of doing business remain crucial for British businesses. On the other hand, it would also provide a boost to investments into the UK from India, already the second largest among nations, he added.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show